18 32

Cited 0 times in

Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic?

DC FieldValueLanguage
dc.contributor.author김현창-
dc.contributor.author박성하-
dc.date.accessioned2021-01-19T08:05:57Z-
dc.date.available2021-01-19T08:05:57Z-
dc.date.issued2020-05-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/181464-
dc.description.abstractAntihypertensive drugs are one of the most widely used pharmacologic agent in the world and it is predominantly used in the elderly subjects. Pneumonia is the most common cause of death in the extremely old subject. During infection and its complication such as sepsis, hypotension could be exacerbated by antihypertensive drugs because homeostasis mechanisms such as sodium balance, renin angiotensin aldosterone system and/or sympathetic nervous system can be mitigated by antihypertensive drug therapy. Severe Acute Respiratory Syndrome-Coronavirus-1 and 2 viral surface protein is known to attach angiotensin converting enzyme 2 (ACE2) on the cell membrane to facilitate viral entry into the cytoplasm. Despite the theoretical concerns of increased ACE2 expression by Renin-Angiotensin-Aldosterone system (RAS) blockade, there is no evidence that RAS inhibitors are harmful during COVID-19 infection and have in fact been shown to be beneficial in animal studies. Therefore, it is recommended to maintain RAS blockade during the current corona virus pandemic.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherBiomed Central-
dc.relation.isPartOfClinical Hypertension-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleIs the use of RAS inhibitors safe in the current era of COVID-19 pandemic?-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Preventive Medicine and Public Health (예방의학교실)-
dc.contributor.googleauthorSungha Park-
dc.contributor.googleauthorHae Young Lee-
dc.contributor.googleauthorEun Joo Cho-
dc.contributor.googleauthorKi Chul Sung-
dc.contributor.googleauthorJuhan Kim-
dc.contributor.googleauthorDae-Hee Kim-
dc.contributor.googleauthorSang-Hyun Ihm-
dc.contributor.googleauthorKwang-Il Kim-
dc.contributor.googleauthorIl-Suk Sohn-
dc.contributor.googleauthorWook-Jin Chung-
dc.contributor.googleauthorHyeon Chang Kim-
dc.contributor.googleauthorSung Kee Ryu-
dc.contributor.googleauthorWook Bum Pyun-
dc.contributor.googleauthorJinho Shin-
dc.contributor.googleauthorKorean Society of Hypertension-
dc.identifier.doi10.1186/s40885-020-00144-0-
dc.contributor.localIdA01142-
dc.contributor.localIdA01512-
dc.contributor.localIdA01512-
dc.relation.journalcodeJ02982-
dc.identifier.eissn2056-5909-
dc.identifier.pmid32391169-
dc.subject.keyword2019 novel coronavirus-
dc.subject.keywordACE inhibitor-
dc.subject.keywordACE2-
dc.subject.keywordAngiotensin receptor blocker-
dc.subject.keywordAntihypertensive drugs-
dc.subject.keywordCOVID-19-
dc.subject.keywordHypertension-
dc.subject.keywordInfection-
dc.subject.keywordPandemic-
dc.subject.keywordSARS-
dc.subject.keywordSARS-CoV-2-
dc.subject.keywordSepsis-
dc.contributor.alternativeNameKim, Hyeon Chang-
dc.contributor.affiliatedAuthor김현창-
dc.contributor.affiliatedAuthor박성하-
dc.contributor.affiliatedAuthor박성하-
dc.citation.volume26-
dc.citation.startPage11-
dc.identifier.bibliographicCitationClinical Hypertension, Vol.26 : 11, 2020-05-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Preventive Medicine and Public Health (예방의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.